Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
THE WOODLANDS, Texas, April 20, 2026 (GLOBE NEWSWIRE) -- Howard Hughes Holdings Inc. (NYSE: HHH) (“the Company” or “Howard Hughes”) today announced the appointment of Marc Grandisson to its Board of...
-
Dublin, April 20, 2026 (GLOBE NEWSWIRE) -- The "Anti-aging Drugs for Dogs Market: Industry Trends and Global Forecasts, Till 2040 - Distribution by Type of Molecule, Type of Biologic, Route of...
-
ZUG, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- Last patient visits for both OCS-01 Phase 3 DIAMOND trials (total 800+ patients) are complete, with topline results expected in June 2026A...
-
ZUG, Sviss, April 20, 2026 (GLOBE NEWSWIRE) -- Síðustu eftirfylgniheimsóknunum í báðum OCS-01 fasa 3 DIAMOND rannsóknaráætlununum (alls 800+ sjúklingar) er lokið og búist er við helstu niðurstöðum í...
-
Last patient visits for both OCS-01 Phase 3 DIAMOND trials (total 800+ patients) are complete, with topline results expected in June 2026A non-invasive topical treatment for diabetic macular edema...
-
WILMETTE, Ill., April 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments...
-
Azetukalner data show significant reductions in seizure frequency across weekly, monthly and multi-year time pointsX-TOLE2 data featured in Late-breaking Science session show 53.2% reduction in...
-
ADAPT OCULUS is the first study to evaluate a targeted treatment for ocular MG, demonstrating that VYVGART significantly improves disease symptoms in this underserved patient populationADAPT SERON,...
-
57.9 Million American Anglers. 220 Million Worldwide. 169 Pending Patent Applications. 850,000+ Lines of Code. Testnet Complete. Mainnet Live. The Outdoor World Has Never Seen Anything Like This. ...
-
Oral presentation highlights additional data from PROGRESS Phase 2b study of pilavapadin supporting selection of 10mg as optimal dose for Phase 3 development in DPNP New data on spasticity further...